Results 111 to 120 of about 4,156,285 (177)

CRAFITY and AFP/PIVKA-II Kinetics Predict Prognosis in Hepatocellular Carcinoma on Immunotherapy. [PDF]

Cancers (Basel)
Lee SW, Huang YJ, Lin YC, Tsai HJ, Chen CC, Chang CH, Lee TY, Peng YC.   +7 more
europepmc   +1 more source

The diagnostic performance of AFP and PIVKA-II models for non-B non-C hepatocellular carcinoma. [PDF]

BMC Res Notes, 2023
Tran VT, Phan TT, Nguyen TB, Le TT, Tran TT, Nguyen AT, Nguyen HT, Nguyen NB, Ho TT, Pho SP, Nguyen TT, Nguyen HT, Mai HT, Pham BT, Nguyen KD, Le BT, Nguyen TT, Nguyen ST.   +17 more
europepmc   +1 more source

Differential Associations of PIVKA-II with Epithelial and Mesenchymal Features in HCC and PDAC. [PDF]

Int J Mol Sci
Farina A, Cicolani G, Viggiani V, Matteo M, Angeloni A, Anastasi E.   +5 more
europepmc   +1 more source

Validation of combined AFP, AFP-L3, and PIVKA II for diagnosis and monitoring of hepatocellular carcinoma in Chinese patients. [PDF]

Heliyon, 2023
Ren T, Hou X, Zhang X, Chen D, Li J, Zhu Y, Liu Z, Yang D.   +7 more
europepmc   +1 more source

Characterization of PIVKA-II Molecular Forms via Size Exclusion Chromatography and Hydrophobic Interaction Chromatography in HCC Patients. [PDF]

J Clin Lab Anal
Kitamura Y, Aoyagi K.
europepmc   +1 more source

Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels.

, 2012
OBJECTIVE: α-Fetoprotein (AFP) and prothrombin induced by the absence of vitamin K or antagonist-II (PIVKA-II) are useful tumor markers for hepatocellular carcinoma (HCC).
전승민, 안상훈, 이관식, 박준용, 김도영, 김승업, 한광협, 강세훈, 김자경, 전재윤   +9 more
core  

Clinical performance of GAAD score, alpha-fetoprotein, and PIVKA-II in diagnosing hepatocellular carcinoma in the Vietnamese cohort. [PDF]

Discov Oncol
Pham TTT, Ho DT, Nguyen TB, Phan HT.
europepmc   +1 more source

Methylated SEPT9 combined with AFP and PIVKA-II is effective for the detection of HCC in high-risk population. [PDF]

BMC Gastroenterol, 2023
Zheng K, Dai L, Zhao Y, Li L, Li W, Zhang X, Su Q, Wu R, Jiang Y, Chen Y, Ran J.   +10 more
europepmc   +1 more source

Early PIVKA-II Response Predicts Treatment Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma. [PDF]

J Hepatocell Carcinoma
Chen CT, Chuang CH, Hsu CH, Shao YY.
europepmc   +1 more source

Diagnostic and Prognostic Nomograms for Hepatocellular Carcinoma Based on PIVKA-II and Serum Biomarkers. [PDF]

Diagnostics (Basel), 2023
An S, Zhan X, Liu M, Li L, Wu J.
europepmc   +1 more source